SS-31vsThymalin

SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable, mitochondria-targeted tetrapeptide with an alternating aromatic-cationic motif that drives its remarkable 1,000-fold concentration within mitochondria. This accumulation is driven by the highly negative mitochondrial membrane potential (-180 mV), which electrostatically attracts the cationic peptide, and by its lipophilic aromatic residues which partition into the inner mitochondrial membrane.

Once concentrated in the inner mitochondrial membrane, SS-31 selectively binds to cardiolipin — a unique dimeric phospholipid found almost exclusively in this membrane. Cardiolipin plays an essential structural role: it anchors cytochrome c to the inner membrane surface, optimizing electron transfer between Complex III and Complex IV of the electron transport chain (ETC). With aging and disease, cardiolipin undergoes peroxidation by reactive oxygen species (ROS), which disrupts its interaction with cytochrome c. Loosened cytochrome c transfers electrons less efficiently, increasing electron leak to molecular oxygen and generating more ROS — creating a vicious cycle of mitochondrial decline.

SS-31 breaks this cycle by stabilizing the cardiolipin-cytochrome c interaction, restoring optimal electron transfer efficiency and reducing ROS generation at the source. It also protects cardiolipin from peroxidation by ROS scavenging through its dimethyltyrosine (Dmt) residue. The downstream effects are profound: restored mitochondrial membrane potential, improved ATP production, reduced oxidative damage to mitochondrial DNA and proteins, and prevention of the mitochondrial permeability transition pore (mPTP) opening that triggers apoptosis. In aged tissues, where mitochondrial dysfunction is a hallmark of cellular decline, SS-31 effectively rejuvenates mitochondrial function toward a younger phenotype. Clinical studies have shown improvements in skeletal muscle energetics, cardiac function, and exercise tolerance in elderly subjects and patients with mitochondrial myopathy.

Thymalin is a complex of short peptides extracted from bovine thymus glands, representing the biologically active fraction of thymic hormones. The thymus gland is the primary organ of T-cell maturation — bone marrow-derived T-cell precursors migrate to the thymus where they undergo positive and negative selection, emerging as mature, immunocompetent CD4+ helper and CD8+ cytotoxic T cells. The thymus produces a suite of peptide hormones that guide this maturation process, and Thymalin contains a mixture of these bioactive peptides.

The peptide complex acts at multiple points in the immune system. It promotes the differentiation of pre-T cells into mature T-cell subsets, restoring the CD4/CD8 ratio toward normal values (typically 1.5-2.5:1 in healthy individuals). It enhances natural killer (NK) cell cytotoxic activity, which is critical for immune surveillance against virus-infected and neoplastic cells. It modulates cytokine production — generally promoting a balanced Th1/Th2 response rather than driving either extreme — and enhances macrophage phagocytic capacity.

The relevance to aging is direct: the thymus undergoes progressive involution (shrinkage) beginning at puberty, and by age 60-70, most thymic tissue has been replaced by fat, with minimal residual T-cell educating capacity. This thymic involution is a major driver of immunosenescence — the age-related decline in immune function that increases susceptibility to infections, cancers, and autoimmune conditions while reducing vaccine responsiveness. Thymalin aims to pharmacologically replace the thymic peptide signals lost through involution, partially restoring the immune system's ability to produce new, functional T cells. Research from the Khavinson group has reported that Thymalin treatment in elderly patients was associated with reduced mortality and improved immune markers over long-term follow-up, though these studies require independent replication in Western clinical settings.